Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Clinical trial NCT03255018 · COMPLETED
Trial details
- NCT number
- NCT03255018
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-15
- Primary completion
- 2022-10-22
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.